ABUS vs GILD

For growth investors, Arbutus Biopharma Corporation (ABUS) is the stronger pick with 128.

2% revenue growth year-over-year, versus 2. 4% for Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. (GILD) offers the better valuation at 19. 8x trailing P/E (15. 7x forward), making it the more compelling value choice. Analysts rate Arbutus Biopharma Corporation (ABUS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +124. 2%, compared to +54. 8% for Arbutus Biopharma Corporation (ABUS). Over 10 years, the gap is even starker: GILD returned +87. 8% versus ABUS's +1. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Gilead Sciences, Inc.

(GILD) is the lower-risk stock at 0. 66β versus Arbutus Biopharma Corporation's 1. 39β — meaning ABUS is approximately 111% more volatile than GILD relative to the S&P 500. On balance sheet safety, Arbutus Biopharma Corporation (ABUS) carries a lower debt/equity ratio of 1% versus 109% for Gilead Sciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arbutus Biopharma Corporation (ABUS) is pulling ahead at 128.

2% versus 2. 4% for Gilead Sciences, Inc. (GILD). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 55. 3% for Arbutus Biopharma Corporation. Over a 3-year CAGR, GILD leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus -237. 9% for Arbutus Biopharma Corporation — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 40. 1% versus -271. 0% for ABUS. At the gross margin level — before operating expenses — GILD leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ABUS: 95.

4% to $8. 50.

In this comparison, GILD (2.

4% yield) pays a dividend. ABUS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Gilead Sciences, Inc.

(GILD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 2. 4% yield). Both have compounded well over 10 years (GILD: +87. 8%, ABUS: +1. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABUS is a small-cap high-growth stock; GILD is a mid-cap quality compounder stock. GILD pays a dividend while ABUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.